Navigation Links
Weight Management is Not Enough for Cannabinoid Type 1 (CB1),Receptor Antagonists to Become a Commercial Success

Huge clinical development program of first-in-class CB1 antagonist rimonabant to show benefits beyond weight reduction and avoid image as life-style drug

BARCELONA, Spain | March 08, 2007 | The Business Intelligence firm La Merie S.L. reported today that Sanofi-Aventis’ first-in-class CB1 antagonist Acomplia (rimonabant) has at least five competitors in clinical stages up to phase III and many more in earlier phases of R&D. While Acomplia received EU approval in June 2006, the FDA requested more time to review the file. Acomplia is indicated for the treatment of patients with obesity or overweight plus cardiometabolic risk factors and achieved EU sales of € 31 mln in its first months in selected markets. However, some countries such as Germany consider Acomplia as a non-reimbursable life-style drug. Sanofi-Aventis is undertaking a huge clinical program to profile Acomplia in additional populations such as in type 2 diabetes (1st line), insulinized patients, dyslipidemia or atherosclerosis. Another field of potential use of CB1 antagonists lies in neuroscience, such as addiction and cognitive disorders. These results and more were found in a search conducted by La Merie Business Intelligence. The competitor analysis of CB1 antagonists can be acquired at www.pipelinereview.com, La Merie’s News Center and Online Store.

Rimonabant has been studied in more than 6,000 patients. Results of the RIO-LIPIDS study showed that a one-year treatment of overweight and obese patients with abnormal lipid levels with once daily rimonabant significantly reduced body weigth by an average of 6.9 kg in comparison to a loss of 1.5 kg in the placebo group. More importantly, it improved a range of cardiometabolic risk factors that may contribute to type 2 diabetes and heart disease. Results of a two-year treatment with rimonabant in the RIO-
'"/>




Page: 1 2 3

Related medicine technology :

1. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
2. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
3. New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People
4. New Data Confirm That Use of Levemir Can Limit Weight Gain
5. Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
6. Choosing Lab Quality Management Software
7. Optimizing Quality Control Data Management
8. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
9. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
10. Vakzine Projekt Management Reports Positive Clinical Trial Results With Their Therapeutic Prostate Cancer Vaccine VPM4001
11. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
Post Your Comments:
(Date:1/6/2009)...BRIDGE, Mass., Jan. 6 Cequent Phar... products to deliver RNAi-based treatments to prev...mpany has recently completed a successful toxicolo...stered tk RNAi therapeutic targeting the primary ...denomatous polyposis). FAP is an inherited gastroi...
(Date:1/5/2009)... SAN JOSE, Calif., Jan. 5 Women un...gesterone medication to help support early,pregna...ms of this medication,can be painful for patients...can be administered by subcutaneous injection or v... better patient tolerance. , With patient w...
(Date:12/27/2008)... SAN DIMAS, Calif., Dec. 27 Accord... are best advised to consume modest doses of,resv...typically provided in 3,to 5 glasses of aged, red...oto: http://www.newscom.com/cgi-bin/prnh/2008060...mega-dose resveratrol alone fails to prolong,the ...
(Date:12/17/2008)...TO, Calif., Dec. 17 PEAK Surgical,...d a new tissue dissection system based on a,propr...ood and Drug,Administration (FDA) has granted the...urgery System for cutting and coagulation of soft ...r, nose and throat), gynecologic,orthopedic, art...
Breaking Medicine Technology:Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 2Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference 3Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 3PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 4EntreMed Teams with JSB Partners to Expedite Partnering of its Aurora Kinase Program 25323 1EntreMed Teams with JSB Partners to Expedite Partnering of its Aurora Kinase Program 25323 2EntreMed Teams with JSB Partners to Expedite Partnering of its Aurora Kinase Program 25323 3Concentric Medical 28R 29 Announces Co Marketing Agreement With InTouch Health 28R 29 to Advance Acute Ischemic Stroke Care 7088 1Concentric Medical 28R 29 Announces Co Marketing Agreement With InTouch Health 28R 29 to Advance Acute Ischemic Stroke Care 7088 2MabVax Therapeutics Closes Two Licensing Agreements With Sloan Kettering Institute for Cancer Research 2820 1MabVax Therapeutics Closes Two Licensing Agreements With Sloan Kettering Institute for Cancer Research 2820 2Dermatologists Score Healthy First for Fans at Final Tennis Tournament Before U S Open 25320 1Dermatologists Score Healthy First for Fans at Final Tennis Tournament Before U S Open 25320 2Dermatologists Score Healthy First for Fans at Final Tennis Tournament Before U S Open 25320 3
...ering-Plough Announces Presentation Of Phase II Tr...onist At The 2007 Annual,Meeting Of The American C...March 16, 2007 /PRNewswire-FirstCall/ --,Schering-... the,Phase II trial of its novel oral thrombin rec...d at the 2007 annual Scientific Sessions,of the of...
...N CARLOS, Calif., March 19, 2007 /PRNewswire-First...l data from the ANTHEM,(Anticoagulation with rNAPc...oking at recombinant nematode anticoagulant protei...ute coronary syndromes,(NSTE-ACS) will be presente...(ACC) 56th Annual Scientific Session taking place ...
Other Medicine Technology:Media Advisory: ACC Updated Schedule 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 2Nuvelo Announces Presentation on rNAPc2 at American College of,Cardiology 56th Annual Scientific Session 3
(Date:1/8/2009)..., Board Decision May Be Revealed Friday, January...re/ -- Today, Service Employees International Uni...ce call of the SEIU International Executive Board ...ome and homecare members out of SEIU United Health...te, but delayed the final decision until tomorrow....
(Date:1/8/2009)..., New Allscripts Prenatal Solution Key Factor in ... CHICAGO and ORLANDO, Fla., Jan. 8 /PRNewswire-Fir...an Associates LLC, one of the largest multi-specia..., has selected the Allscripts Enterprise(TM) Elect...their 80 physicians in 18 offices across Central F...
(Date:1/8/2009)..., BETHESDA, Md., Jan. 8 /PRNewswire-FirstCall/ -...pleased to announce that throughout the fourth qua..., Orthotics Center, Rocky Mountain Orthotic-Prosth...Services, Inc., First Coast Orthotics & Prosth.... These acquisitions add patient care centers to e...
(Date:1/8/2009)..., WASHINGTON, Jan. 8 T... D. Olson has been named director, chemical and fo...ices Policy program. Olson, who was formerly deput... Committee on Environment and Public Works, brings...licy and consumer advocacy to Pew. , , "We are...
Breaking Medicine News(10 mins):Health News:SEIU Decision to Force Transfer of Long-Term Care Members Out of United Healthcare Workers Delayed 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2Health News:Veteran Environmental Health Expert Erik D. Olson to Join Pew 2
...of Texas Health Center at Tyler has discovered how...ocess works. Once the process// is thoroughly unde...ulate it, thus preventing excessive bleeding or bl...er, Ph.D., and his team are published in the Aug. ...
...ive up smoking may be more successful than anyone ... to a new study in the July-August 2006// Nursing ... nurses are widely recognized as central to global... of tobacco use," said Dr. Molly C. Dougherty, Nur...
...accepted as a hazard of aging, but researchers act...es are a consequence of aging// or not. Researcher... the Scripps Research Institute have now conducted...is critical for diseases like Alzheimer's. Harmfu...
...mu and Kashmir is having a severe impact on the me...ildren.// More and more women are knocking on th...fe-torn state. Over 50 percent of some 60,000 peop... mental disorders in the past decade have been wom...
Other Medicine News:Health News:Scientist Discovers Crucial Part of Blood-Clotting Process 2Health News:Nurses Can Play Big Role In Helping Patients Quit Smoking 2Health News:Aging Critical For Alzheimer's Disease 2Health News:Aging Critical For Alzheimer's Disease 3Health News:More People Seeking Treatment for Mental Illness in Strife-torn Kashmir 2
The 15 and 18 Sony Flat Screen Monitors with articulating arm can be used in conjunction with existing surgical monitors or as replacements.
Colour video monitors.
The A3 3-Chip Camera includes digital processing, seamless autoshutter, industry-leading reliability, white balance with memory function, ease of operation, and a 2 year warranty.
Camera and light source in one compact "Plug-and-Play" device.
Medicine Products: